Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care. It is developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide. The company's lead product candidate includes NeuVax (nelipepimut-S or E75), which is in Phase 3 clinical trials for preventing the recurrence of breast cancer. It also develops Folate Binding Protein-E39, a targeted vaccine that is in Phase 1/2 clinical trials for the prevention of recurrence in gynecological cancers, such as ovarian and endometrial adenocarconimas. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Oswego, Oregon.
Address
Suite 208, 310 N. State Street
LAKE OSWEGO, OR 97034
United States
LAKE OSWEGO, OR 97034
United States
Website
www.galenabiopharma.comKey stats and ratios
| Q3 (Sep '13) | 2012 | |
| Net profit margin | -793.76% | - |
| Operating margin | -589.15% | - |
| EBITD margin | - | - |
| Return on average assets | -48.61% | -77.54% |
| Return on average equity | -149.45% | -176.01% |
| Employees | 12 |
No comments:
Post a Comment